By Katherine Hamilton
Masimo forecast a stronger than expected 2025 as it refocuses on its core medical business.
In its fourth-quarter earnings report, the medical technology maker guided for adjusted earnings per share of $5.10 to $5.40 in 2025, ahead of the $4.69 a share analysts polled by FactSet were expecting. It expects healthcare revenue to be $1.50 million to $1.53 million this year, which would be an 8% to 11% increase.
Masimo posted a fourth-quarter loss of $349.6 million, or $6.52 a share, in the three months ended Dec. 28, compared with a profit of $34 million, or 63 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were $1.80, ahead of the $1.43 forecast by analysts, according to FactSet.
Revenue rose 9%, to $600.7 million. Analysts surveyed by FactSet forecast revenue of $593 million.
Masimo is currently undergoing a strategic realignment to focus on its core healthcare business. In January, the Irvine, Calif., company named Katie Szyman, who was head of patient monitoring at Becton Dickinson and Co., as its new chief executive.
"As a result of our strategic realignment efforts in the fourth quarter, we expect to see increased earnings and cash flow in 2025 and beyond," Szyman said.
Operating expenses more than doubled compared with the previous year, contributing to the overall loss.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 25, 2025 16:45 ET (21:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。